Trial results

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

NCT03130426 on ClinicalTrials.gov · last registry update 2020-11-13

A small phase 3 — 161 participants, against a typical 424. The sponsor logged completion for 30 June 2019. Primary outcome, as filed: The first occurrence of diabetes relapse. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P3

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Population Health Research Institute

Sponsor type

Other

Enrollment

161

Started

2017-06-27

Primary completion

2019-06-30 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

The first occurrence of diabetes relapse

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.